From ARPA-H to Basilea: What Phare Bio’s new deal reveals about biotech partnerships
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.